KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Deffered Revenue (2017 - 2023)

Historic Non-Current Deffered Revenue for BeOne Medicines (ONC) over the last 6 years, with Q4 2023 value amounting to $300000.0.

  • BeOne Medicines' Non-Current Deffered Revenue fell 9928.62% to $300000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $300000.0, marking a year-over-year decrease of 9928.62%. This contributed to the annual value of $300000.0 for FY2023, which is 9928.62% down from last year.
  • BeOne Medicines' Non-Current Deffered Revenue amounted to $300000.0 in Q4 2023, which was down 9928.62% from $300000.0 recorded in Q3 2023.
  • BeOne Medicines' 5-year Non-Current Deffered Revenue high stood at $220.3 million for Q4 2021, and its period low was $300000.0 during Q3 2023.
  • Over the past 4 years, BeOne Medicines' median Non-Current Deffered Revenue value was $52.3 million (recorded in 2021), while the average stood at $81.6 million.
  • In the last 5 years, BeOne Medicines' Non-Current Deffered Revenue soared by 18676.73% in 2022 and then tumbled by 9979.99% in 2023.
  • BeOne Medicines' Non-Current Deffered Revenue (Quarter) stood at $8.2 million in 2019, then skyrocketed by 2573.41% to $220.3 million in 2021, then tumbled by 80.92% to $42.0 million in 2022, then tumbled by 99.29% to $300000.0 in 2023.
  • Its last three reported values are $300000.0 in Q4 2023, $300000.0 for Q3 2023, and $24.3 million during Q2 2023.